Cargando…

PB1935: MANAGEMENT OF NON-SEVERE APLASTIC ANEMIA: LABORATORY WORKUP AND TREATMENT PATTERNS.

Detalles Bibliográficos
Autores principales:	Cassanello, G., Giannotta, J. A., Cro, L., Barbieri, M., Barcellini, W., Fattizzo, B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431448/ http://dx.doi.org/10.1097/01.HS9.0000850580.84056.1d

Ejemplares similares

PB1932: GENERIC ELTHROMBOPAG WITH STANDARD IMMUNOSUPPRESSIVE THERAPY IN SEVERE APLASTIC ANEMIA
por: Ranjit Kumar, C., et al.
Publicado: (2022)

PB2055: PREGNANCY IN PATIENTS WITH APLASTIC ANEMIA – CLINICAL OBSERVATIONS
por: Shilova, Elene, et al.
Publicado: (2023)

PB2037: NEW TERT VARIANT IN A FAMILY WITH APLASTIC ANEMIA
por: Virijevic, Marijana, et al.
Publicado: (2023)

PB2066: SYSTEMIC LUPUS ERYTHEMATOSUS-INDUCED AMEGAKARYOCYTIC THROMBOCYTOPENIA AND SUBSEQUENT APLASTIC ANEMIA
por: Seong, Gyuhee, et al.
Publicado: (2023)

PB2046: CHANGINGS IN GENETIC DEFINITION AND MANAGEMENT OF ACQUIRED APLASTIC ANEMIA: A SINGLE CENTER EXPERIENCE
por: Bortolotti, Marta, et al.
Publicado: (2023)

PB2069: ELTROMBOPAG WITH IMMUNO SUPPRESSIVE THERAPY IN SEVERE ACQUIRED APLASTIC ANEMIA IN CHILDREN AND ADOLESCENTS: A MONOCENTRIC EXPERIENCE
por: Sayed, Nesrine Ben, et al.
Publicado: (2023)

Mesenchymal Stem Cells in Aplastic Anemia and Myelodysplastic Syndromes: The “Seed and Soil” Crosstalk
por: Fattizzo, Bruno, et al.
Publicado: (2020)

PB1940: ACQUIRED APLASTIC ANEMIA: THE CHALLENGE OF TREATMENT IN MEXICO. SINGLE HEMATOLOGY CENTER EXPERIENCE
por: Guajardo Leal, M. L., et al.
Publicado: (2022)

PB1941: PRELIMINARY EXPLORATION OF PROLONGED USE OF ELTROMBOPAG IN PATIENTS WITH NAÏVE SEVERE APLASTIC ANEMIA IN THE REAL WORLD: DURATION AND EFFICACY
por: Li, R., et al.
Publicado: (2022)

PB2049: THE EFFICACY OF HETROMBOPAG PLUS CYCLOSPORINE A IN PATIENTS WITH TRANSFUSION-DEPENDENT NON-SEVERE APLASTIC ANEMIA: A PROSPECTIVE REGISTRY STUDY
por: Gong, Yuemin, et al.
Publicado: (2023)

PB1950: MASS CYTOMETRY ANALYSIS IDENTIFIES T CELL IMMUNE SIGNATURE FOR APLASTIC ANEMIA AND PREDICTS RESPONSE TO CYCLOSPORINE
por: Zhang, L., et al.
Publicado: (2022)

PB2038: THE POTENTIAL MECHANISM OF TCM TREATMENT OF CHRONIC APLASTIC ANEMIA BASED ON DATA MINING AND NETWORK PHARMACOLOGY
por: Si, Yuping, et al.
Publicado: (2023)

PB2431: OUTCOME OF HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SEVERE APLASTIC ANEMIA IN PEDIATRIC POPULATION - A SINGLE CENTER EXPERIENCE FROM PUBLIC HOSPITAL
por: Patil, Rajesh, et al.
Publicado: (2023)

PB2471: EFFECT OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH MODIFIED FC PRETREATMENT REGIMEN ON SEX HORMONE LEVELS IN CHILDREN WITH SEVERE APLASTIC ANEMIA
por: MA, Liangming, et al.
Publicado: (2023)

PB2041: COMPARISON OF ELTROMBOPAG AND AVATROMBOPAG IN THE TREATMENT OF REFRACTORY/RELAPSED APLASTIC ANEMIA, A SINGLE CENTER STUDY IN CHINA
por: Zhang, Zhuxin, et al.
Publicado: (2023)

PB2479: ELTROMBOPAG, BUT NOT AVATROMBOPAG, REGULATES BONE MARROW MICROENVIRONMENT MIMICKING APLASTIC ANEMIA THROUGH DOWN-REGULATION OF FERROPTOSIS INHIBITOR
por: Ji, Jiang, et al.
Publicado: (2023)

PB2550: EXPLORATION OF B-CELL RECEPTOR AND T-CELL RECEPTOR REPERTOIRES REVEALS DISTINCT MECHANISMS IN PURE RED CELL APLASIA, AUTOIMMUNE HEMOLYTIC ANEMIA AND APLASTIC ANEMIA
por: Zhang, Ruoxi, et al.
Publicado: (2023)

PB2252: A PATIENT WITH SEVERE APLASTIC ANEMIA UNDERWENT ALLOGENEIC HEMATOPOIETIC TRANSPLANTATION. EVIDENCE-BASED NURSING CARE OF PATIENTS COMPLICATED WITH ORAL AND LABIAL TISSUE ULCERATION
por: Wang, LI, et al.
Publicado: (2023)

PB2428: CLINICAL EFFICACY AND HEALTH-RELATED QUALITY OF LIFE IN SEVERE APLASTIC ANEMIA TREATED BY UMBILICAL CORD BLOOD TRANSPLANTATION: A CROSS-SECTIONAL SURVEY IN CHINA
por: LI, Ping, et al.
Publicado: (2023)

PB2466: PERIPHERAL BLOOD AS GRAFT SOURCE FOR APLASTIC ANEMIA TRANSPLANT: OUTCOMES OF YOUNG ADULTS AND ADULTS IN A MEXICAN PUBLIC HOSPITAL
por: Sotomayor Duque, Guillermo, et al.
Publicado: (2023)

Deciphering treatment patterns in non-severe/moderate aplastic anemia: an international observational study
por: Fattizzo, Bruno, et al.
Publicado: (2023)

PB1935: CARDIOTOXICITY AND SAFETY OF BRUTON’S TYROSINE KINASE INHIBITORS: A REVIEW OF REAL-WORLD OBSERVATIONAL EVIDENCE
por: Balijepalli, Chakrapani, et al.
Publicado: (2023)

PB1949: ELTROMBOPAG IN CHINESE PATIENTS WITH REFRACTORY OR RELAPSED SEVERE APLASTIC ANEMIA: A NON-RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE II STUDY ASSESSING THE SAFETY AND EFFICACY OF ELTROMBOPAG
por: Chang, H., et al.
Publicado: (2022)

Small Paroxysmal Nocturnal Hemoglobinuria Clones in Autoimmune Hemolytic Anemia: Clinical Implications and Different Cytokine Patterns in Positive and Negative Patients
por: Fattizzo, Bruno, et al.
Publicado: (2020)

PB2546: DIAGNOSTIC POWER OF ERYTHROCYTE AND RETICULOCYTE AUTOMATIC PARAMETERS IN THE SCREENING FOR CONGENITAL HEMOLYTIC ANEMIAS
por: Bianchi, Paola, et al.
Publicado: (2023)

PB1990: GLYCOLYTIC ACTIVITY AND EFFECT OF EX-VIVO TREATMENT WITH THE PYRUVATE KINASE (PK) ACTIVATOR AG-946 IN RED BLOOD CELLS FROM LOW-RISK MYELODYSPLASTIC SYNDROMES PATIENTS: A PROOF-OF-CONCEPT STUDY
por: Fattizzo, Bruno, et al.
Publicado: (2023)

PB2060: THE RESULTS OF A FOUR YEARS LONG OBSERVATION OF APLASTIC AMENIA PATIENTS DEPENDING ON A PROGRAM OF IMMUNOSUPPRESSIVE THERAPY
por: Chebykina, Daria, et al.
Publicado: (2023)

PB2693: ANEMIA IN HEMATOLOGIC MALIGNANCIES: NOT ONLY A SYMPTOM.
por: Hari, Oumayma, et al.
Publicado: (2023)

PB2030: HYPERCHROMIC ANEMIA AS THE FIRST MANIFESTATION OF MYELOPROLIFERATIVE DISEASE
por: Lepkov, Sergey, et al.
Publicado: (2023)

PB2242: MANAGEMENT OF AUTOIMMUNE HEMOLYTIC ANEMIA.RETROSPECTIVE STUDY OF A SINGLE CENTER
por: Hortensia-Marioara, I., et al.
Publicado: (2022)

PB2345: ADAPTING PATIENT EDUCATIONAL APPROACHES IN PYRUVATE KINASE DEFICIENCY: EUROPE AND NORTH AMERICA FINDINGS FROM THE AAC PATIENT AND CAREGIVER SURVEY
por: Barcellini, W., et al.
Publicado: (2022)

PB2552: VAYHIA: A RANDOMIZED, DOUBLE-BLIND, PHASE III TRIAL TO ASSESS THE EFFICACY AND SAFETY OF IANALUMAB VS PLACEBO IN PATIENTS WITH WARM AUTOIMMUNE HEMOLYTIC ANEMIA THAT FAILED ≥1 LINE OF TREATMENT
por: Barcellini, Wilma, et al.
Publicado: (2023)

PB2569: ALAS! PORPHYRIA OR SIDEROBLASTIC ANEMIA? A CASE REPORT
por: Catana, Alina, et al.
Publicado: (2023)

PB2611: EVANS SYNDROME: DISEASE AWARENESS AND CLINICAL MANAGEMENT IN A NATION-WIDE ITALIAN SURVEY
por: Fattizzo, Bruno, et al.
Publicado: (2023)

Low-Risk Myelodysplastic Syndrome Revisited: Morphological, Autoimmune, and Molecular Features as Predictors of Outcome in a Single Center Experience
por: Fattizzo, Bruno, et al.
Publicado: (2022)

PB2556: MEGALOBLASTIC ANEMIA: EPIDEMIOLOGICAL, CLINICAL, AND ETIOLOGICAL PROFILE: ABOUT 200 CASES.
por: Zahra, Kmira, et al.
Publicado: (2023)

PB2545: HAEMATOLOGICAL INDICES IN DIFFERENTIAL DIAGNOSIS OF MICROCYTIC ANEMIAS, A REGIONAL STUDY
por: Myrtaj, Rialda, et al.
Publicado: (2023)

PB2254: ASSOCIATION BETWEEN TNF-ALPHA LEVELS AND TNF-ALPHA 238 ALLELES POLYMORPHISMS AND SEVERITY OF ANEMIA AMONG SUDANESE CHILDREN WITH FALCIPARUM MALARIA
por: Mohamedahmed, K. A.
Publicado: (2022)

PB2557: CHARACTERISTICS OF AUTOIMMUNE HEMOLYTIC ANEMIA IN ADULTS: A CASE SERIES OF 35 PATIENTS
por: Hanani, Hind, et al.
Publicado: (2023)

PB2563: IRON DEFICIENCY ANEMIA: A MONOCENTRIC EXPERIENCE OF THE HAEMATOLOGY DEPARTMENT OF MONASTIR, TUNISIA
por: Bouhoula, Donia, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_dfhmcnh1797d62hja2s266r2oa